Premium
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysis
Author(s) -
Han Q. L.,
Zhou Y. H.,
Lyu Y.,
Yan H.,
Dai G. H.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12655
Subject(s) - gemcitabine , oncology , ribonucleotide reductase , pancreatic cancer , chemotherapy , meta analysis , medicine , cancer research , cancer , biology , gene , genetics , protein subunit
Summary What is known and objective The prognostic value of ribonucleotide reductase M1 ( RRM 1) in patients with pancreatic cancer receiving gemcitabine chemotherapy has been evaluated in several studies. However, the conclusions remain controversial. Methods By searching the PubMed and Embase databases, we conducted a meta‐analysis to evaluate the prognostic significance of RRM 1 expression in patients with pancreatic cancer receiving gemcitabine chemotherapy. Studies were pooled, and the hazard ratio ( HR ) and its corresponding 95% confidence interval ( CI ) were calculated. Results Nine relevant articles were included for this meta‐analysis study. Our results revealed that the high‐ RRM 1 expression patients had significantly poorer overall survival ( HR = 1.70, 95% CI = 1.33‐2.16, P heterogeneity = .061, I 2 = 44.8%) and disease‐free survival ( HR = 1.84, 95% CI = 1.56‐2.18, P heterogeneity = .669, I 2 = 0%) than the low‐ RRM 1 expression patients. Furthermore, a statistically significant association between RRM 1 expression and OS was found among both Japanese ( HR = 1.80, 95% CI = 1.36‐2.37, P heterogeneity = .843, I 2 = 0%) and American patients ( HR = 1.76, 95% CI = 1.60‐1.94, P heterogeneity = .439, I 2 = 0%). What is new and conclusion In conclusion, the expression of RRM 1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. RRM 1 expression assessment could provide more detailed information for patients with pancreatic cancer and could be used to optimize therapeutic schemes.